Robert W. Baird analyst Brian Skorney maintained a Buy rating on Mirum Pharmaceuticals (MIRM) on April 29 and set a price target of $30.00. The company’s shares closed last Friday at $19.54.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 5.2% and a 50.9% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Intellia Therapeutics.
Currently, the analyst consensus on Mirum Pharmaceuticals is a Strong Buy with an average price target of $41.00, which is an 116.4% upside from current levels. In a report issued on April 29, H.C. Wainwright also maintained a Buy rating on the stock with a $52.00 price target.
See today’s analyst top recommended stocks >>
Based on Mirum Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $37.2 million. In comparison, last year the company had a GAAP net loss of $17.95 million.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MIRM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
